Gilead published clinical data on GS-9688, a new functional drug for hepatitis B
-
Last Update: 2021-02-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Gilead, the US pharmaceutical giant, released new clinical data on
, a functional cure for hepatitis B.About GS-9688GS-9688 is an oral, selective tooll-like subject 8 (TLR8) small molecular agonist.In a multi-center, randomized, double-blind Phase II study of 48 patients with chronic HBV infections who had achieved virological suppression, GS-9688 (once a week oral) combined oral antiviral drugs (OAVs) were well toned during extended administration and showed pharmacological activity of dose dependence.The clinical activity of GS-9688 was also assessed: 5% of patients treated with GS-9688 had a decrease in HBSAg or HBeAg levels ≥1 log10IU/mL at the 24th week of treatment.data support ongoing GS-9688 studies and new combinations aimed at achieving functional cures for HBV.The safety and ability of GS-9688 has not been determined, and the drug is a research compound that has not been approved by the FDA or any other regulatory agency. (Drug Information Network)
)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
